Novel loci interacting epistatically with bone morphogenetic protein receptor 2 cause familial pulmonary arterial

Laura Rodriguez-Murillo1, Ryan Subaran, William C L Stewart

  • 1Division of Statistical Genetics, Department of Biostatistics, Columbia University Medical Center, New York, New York, USA.

Abstract

Insights

Genetic modifiers influence familial pulmonary arterial hypertension (FPAH) in BMPR2 mutation carriers. A genome-wide scan identified new loci, particularly 3q22, that may improve FPAH risk prediction.

Area of Science:

  • Genetics
  • Pulmonary Hypertension
  • Molecular Biology

Background:

  • Familial pulmonary arterial hypertension (FPAH) is a rare, autosomal-dominant disease with incomplete penetrance.
  • Bone morphogenetic protein receptor 2 (BMPR2) mutations are found in 70% of FPAH patients, but only 10-20% develop the disease.
  • Genetic and environmental factors likely modify BMPR2 mutation penetrance.

Purpose of the Study:

  • To identify genetic loci influencing FPAH expression in BMPR2 mutation carriers.
  • To understand the genetic basis of variable disease penetrance in FPAH.

Main Methods:

  • Genome-wide linkage scan in 15 FPAH families with BMPR2 mutations.
  • Utilized dense single-nucleotide polymorphism (SNP) arrays and a novel multi-scan linkage procedure.
  • Employed non-parametric bootstrap and LOD-score maximization for high-resolution locus identification.

Main Results:

  • Identified linkage evidence in four chromosomal regions: 3q22, 3p12, 2p22, and 13q21.
  • The 3q22 locus showed the strongest linkage (median LOD = 3.43) and appears to interact epistatically with BMPR2.
  • The identified regions contain candidate genes potentially interacting with BMPR2.

Conclusions:

  • Genotypes at newly identified loci, especially 3q22, may enhance FPAH risk prediction in BMPR2 mutation carriers.
  • These findings suggest potential new therapeutic targets for FPAH.
  • Further research into these loci can elucidate FPAH pathogenesis.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Epistasis01:39

Epistasis

In addition to multiple alleles at the same locus influencing traits, numerous genes or alleles at different locations may interact and influence phenotypes in a phenomenon called epistasis. For example, rabbit fur can be black or brown depending on whether the animal is homozygous dominant or heterozygous at a TYRP1 locus. However, if the rabbit is also homozygous recessive at a locus on the tyrosinase gene (TYR), it will have an unshaded coat that appears white, regardless of its TYRP1...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...